FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964108702> ?p ?o ?g. }

• W1964108702 endingPage "1370" @default.
• W1964108702 startingPage "1363" @default.
• W1964108702 abstract "Background & Aims The diagnosis of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is limited by the need for liver biopsy. We aimed at testing the accuracy of cytokeratin-18 fragment (CK-18), adipocyte fatty acid binding protein (AFABP) and fibroblast growth factor 21 (FGF21) for the diagnosis of NAFLD and NASH. Methods 146 patients with biopsy-proven NAFLD and 74 age- and gender-matched healthy controls were included. Serum CK-18, AFABP and FGF21 levels were determined by enzyme-linked immunosorbent assay. Results Serum CK-18, AFABP, and FGF21 increased in a stepwise fashion in control subjects (median 103 U/L, 15.4 ng/ml, and 104 pg/ml), patients with non-NASH NAFLD (263 U/L, 18.9 ng/ml, and 249 pg/ml) and NASH (418 U/L, 19.4 ng/ml, and 354 pg/ml) (p <0.001, 0.060, and 0.016, respectively). The area under receiver-operating characteristics curve to diagnose NAFLD and NASH was 0.91 and 0.70 for CK-18, 0.66 and 0.59 for AFABP, and 0.84 and 0.62 for FGF21. At cut-offs of 203 and 670 U/L, CK-18 had 71% negative predictive value (NPV) and 77% positive predictive value (PPV) to exclude and diagnose NASH. A 2-step approach measuring CK-18 followed by FGF21 further improved the NPV to 74% and PPV to 82%. In a validation cohort of 51 patients with paired liver biopsies, the NPV and PPV of the 2-step approach were 67% and 78%, respectively. Conclusions CK-18 is the most accurate biomarker for NAFLD and NASH. A two-step approach using CK-18 and FGF21 further improves the accuracy in diagnosing NASH. The diagnosis of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) is limited by the need for liver biopsy. We aimed at testing the accuracy of cytokeratin-18 fragment (CK-18), adipocyte fatty acid binding protein (AFABP) and fibroblast growth factor 21 (FGF21) for the diagnosis of NAFLD and NASH. 146 patients with biopsy-proven NAFLD and 74 age- and gender-matched healthy controls were included. Serum CK-18, AFABP and FGF21 levels were determined by enzyme-linked immunosorbent assay. Serum CK-18, AFABP, and FGF21 increased in a stepwise fashion in control subjects (median 103 U/L, 15.4 ng/ml, and 104 pg/ml), patients with non-NASH NAFLD (263 U/L, 18.9 ng/ml, and 249 pg/ml) and NASH (418 U/L, 19.4 ng/ml, and 354 pg/ml) (p <0.001, 0.060, and 0.016, respectively). The area under receiver-operating characteristics curve to diagnose NAFLD and NASH was 0.91 and 0.70 for CK-18, 0.66 and 0.59 for AFABP, and 0.84 and 0.62 for FGF21. At cut-offs of 203 and 670 U/L, CK-18 had 71% negative predictive value (NPV) and 77% positive predictive value (PPV) to exclude and diagnose NASH. A 2-step approach measuring CK-18 followed by FGF21 further improved the NPV to 74% and PPV to 82%. In a validation cohort of 51 patients with paired liver biopsies, the NPV and PPV of the 2-step approach were 67% and 78%, respectively. CK-18 is the most accurate biomarker for NAFLD and NASH. A two-step approach using CK-18 and FGF21 further improves the accuracy in diagnosing NASH." @default.
• W1964108702 created "2016-06-24" @default.
• W1964108702 creator A5007585753 @default.
• W1964108702 creator A5009718905 @default.
• W1964108702 creator A5011835164 @default.
• W1964108702 creator A5028968910 @default.
• W1964108702 creator A5035371564 @default.
• W1964108702 creator A5035912485 @default.
• W1964108702 creator A5045062607 @default.
• W1964108702 creator A5046528197 @default.
• W1964108702 creator A5061484061 @default.
• W1964108702 creator A5062640483 @default.
• W1964108702 creator A5066695904 @default.
• W1964108702 creator A5087968813 @default.
• W1964108702 date "2012-06-01" @default.
• W1964108702 modified "2023-10-18" @default.
• W1964108702 title "Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers" @default.
• W1964108702 cites W1964974443 @default.
• W1964108702 cites W1966628894 @default.
• W1964108702 cites W1969295126 @default.
• W1964108702 cites W1973450715 @default.
• W1964108702 cites W1983417944 @default.
• W1964108702 cites W1992204676 @default.
• W1964108702 cites W2001837599 @default.
• W1964108702 cites W2004109343 @default.
• W1964108702 cites W2005063766 @default.
• W1964108702 cites W2014330519 @default.
• W1964108702 cites W2016617561 @default.
• W1964108702 cites W2022956561 @default.
• W1964108702 cites W2047257800 @default.
• W1964108702 cites W2052663490 @default.
• W1964108702 cites W2059220708 @default.
• W1964108702 cites W2060847352 @default.
• W1964108702 cites W2067740038 @default.
• W1964108702 cites W2080342985 @default.
• W1964108702 cites W2082972253 @default.
• W1964108702 cites W2097481704 @default.
• W1964108702 cites W2098518093 @default.
• W1964108702 cites W2106937897 @default.
• W1964108702 cites W2120056458 @default.
• W1964108702 cites W2131810890 @default.
• W1964108702 cites W2136847524 @default.
• W1964108702 cites W2143104968 @default.
• W1964108702 cites W2153997209 @default.
• W1964108702 cites W2159469729 @default.
• W1964108702 cites W2163803773 @default.
• W1964108702 cites W2169332405 @default.
• W1964108702 doi "https://doi.org/10.1016/j.jhep.2011.12.025" @default.
• W1964108702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22314419" @default.
• W1964108702 hasPublicationYear "2012" @default.
• W1964108702 type Work @default.
• W1964108702 sameAs 1964108702 @default.
• W1964108702 citedByCount "183" @default.
• W1964108702 countsByYear W19641087022012 @default.
• W1964108702 countsByYear W19641087022013 @default.
• W1964108702 countsByYear W19641087022014 @default.
• W1964108702 countsByYear W19641087022015 @default.
• W1964108702 countsByYear W19641087022016 @default.
• W1964108702 countsByYear W19641087022017 @default.
• W1964108702 countsByYear W19641087022018 @default.
• W1964108702 countsByYear W19641087022019 @default.
• W1964108702 countsByYear W19641087022020 @default.
• W1964108702 countsByYear W19641087022021 @default.
• W1964108702 countsByYear W19641087022022 @default.
• W1964108702 countsByYear W19641087022023 @default.
• W1964108702 crossrefType "journal-article" @default.
• W1964108702 hasAuthorship W1964108702A5007585753 @default.
• W1964108702 hasAuthorship W1964108702A5009718905 @default.
• W1964108702 hasAuthorship W1964108702A5011835164 @default.
• W1964108702 hasAuthorship W1964108702A5028968910 @default.
• W1964108702 hasAuthorship W1964108702A5035371564 @default.
• W1964108702 hasAuthorship W1964108702A5035912485 @default.
• W1964108702 hasAuthorship W1964108702A5045062607 @default.
• W1964108702 hasAuthorship W1964108702A5046528197 @default.
• W1964108702 hasAuthorship W1964108702A5061484061 @default.
• W1964108702 hasAuthorship W1964108702A5062640483 @default.
• W1964108702 hasAuthorship W1964108702A5066695904 @default.
• W1964108702 hasAuthorship W1964108702A5087968813 @default.
• W1964108702 hasConcept C106646824 @default.
• W1964108702 hasConcept C126322002 @default.
• W1964108702 hasConcept C170493617 @default.
• W1964108702 hasConcept C2775934546 @default.
• W1964108702 hasConcept C2777766500 @default.
• W1964108702 hasConcept C2778772119 @default.
• W1964108702 hasConcept C2779134260 @default.
• W1964108702 hasConcept C2779478299 @default.
• W1964108702 hasConcept C58471807 @default.
• W1964108702 hasConcept C71924100 @default.
• W1964108702 hasConcept C74373430 @default.
• W1964108702 hasConcept C90924648 @default.
• W1964108702 hasConceptScore W1964108702C106646824 @default.
• W1964108702 hasConceptScore W1964108702C126322002 @default.
• W1964108702 hasConceptScore W1964108702C170493617 @default.
• W1964108702 hasConceptScore W1964108702C2775934546 @default.
• W1964108702 hasConceptScore W1964108702C2777766500 @default.
• W1964108702 hasConceptScore W1964108702C2778772119 @default.
• W1964108702 hasConceptScore W1964108702C2779134260 @default.
• W1964108702 hasConceptScore W1964108702C2779478299 @default.

• next